In This Article:
As European markets navigate a challenging landscape marked by new trade tariffs and economic uncertainties, investors are increasingly seeking companies that demonstrate resilience and potential for growth. In this environment, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 11.8% | 40.8% |
| Elicera Therapeutics (OM:ELIC) | 27.8% | 97.2% |
| Vow (OB:VOW) | 13.1% | 111.2% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
| XTPL (WSE:XTP) | 27.9% | 118% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
| CD Projekt (WSE:CDR) | 29.7% | 36.8% |
| Ortoma (OM:ORT B) | 27.7% | 68.6% |
| Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
| Circus (XTRA:CA1) | 26% | 51.4% |
Below we spotlight a couple of our favorites from our exclusive screener.
P/F Bakkafrost
Simply Wall St Growth Rating: ★★★★☆☆
Overview: P/F Bakkafrost, along with its subsidiaries, is engaged in the production and sale of salmon products across North America, Western Europe, Eastern Europe, Asia, and other international markets; it has a market cap of NOK29.34 billion.
Operations: The company generates revenue from various segments, including Sales and Other (DKK10.21 billion), Farming Faroe Islands (DKK3.97 billion), Fishmeal, Oil and Feed (DKK2.73 billion), Farming Scotland (DKK1.84 billion), Services (DKK894.61 million), Freshwater Faroe Islands (DKK782.05 million), and Freshwater Scotland (DKK117.26 million).
Insider Ownership: 13.3%
Earnings Growth Forecast: 36.6% p.a.
P/F Bakkafrost, a company with significant insider ownership, has demonstrated mixed financial performance recently. Although its net income decreased to DKK 656.6 million from DKK 955.57 million year-on-year, the company's earnings are forecasted to grow significantly by 36.55% annually, outpacing the Norwegian market's growth rate of 7.9%. Despite trading at a substantial discount to its estimated fair value and experiencing lower profit margins than last year, revenue is expected to increase by 13.5% annually.
-
Unlock comprehensive insights into our analysis of P/F Bakkafrost stock in this growth report.
-
Our valuation report unveils the possibility P/F Bakkafrost's shares may be trading at a discount.
RaySearch Laboratories
Simply Wall St Growth Rating: ★★★★★☆
Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer care across various regions including the Americas, Europe, Africa, the Asia-Pacific, and the Middle East, with a market cap of SEK7.71 billion.